Accelerated Intermittent Theta-Burst Stimulation Aids Treatment-Resistant Bipolar Depression
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 24, 2024 -- Accelerated intermittent theta-burst stimulation (aiTBS) is significantly more effective than sham stimulation for depressive symptom reduction in patients with treatment-resistant bipolar depression, according to a study published online July 10 in JAMA Psychiatry.
Yvette I. Sheline, M.D., from the University of Pennsylvania Perelman School of Medicine in Philadelphia, and colleagues assessed whether aiTBS is clinically effective for treatment-refractory bipolar depression. Analysis included 24 participants randomly assigned to active (12 patients) or sham (12 patients) aiTBS. The intervention included 10 sessions per day of imaging-guided active or sham aiTBS for five days with one session per hour at 90 percent resting motor threshold for 90,000 pulses total.
The researchers found that at one month follow-up, Montgomery-Åsberg Depression Rating Scale scores were significantly lower in the active group (mean, 30.4 at baseline; 10.5 after treatment) than in the sham group (28.0 at baseline; 25.3 after treatment).
"The findings suggest that aiTBS in carefully selected patients offers a new treatment option for this difficult-to-treat illness," the authors write. "Further trials are needed to determine aiTBS durability and to compare with other treatments."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-25 01:15
Read more
- UCB Receives U.S. FDA Approval for Bimzelx (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate to Severe Hidradenitis Suppurativa
- Work-Related Stress Linked to Lower Odds of Average, Optimal Heart Health
- Most Adults Lack Knowledge About Pancreatic Cancer
- About 1 in 10 U.S. Adults Have High Cholesterol
- In-Utero Sugar Restriction Cuts Offspring's Risk for Diabetes, Hypertension
- Clinical Practice Guidelines Updated for Primary Prevention of Stroke
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions